Hormone Therapy
Information
- Drug Name
- Hormone Therapy
- Description
- Entry(CIViC)
- 5
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04619069 | Active, not recruiting | Phase 1/Phase 2 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | October 27, 2020 | October 2027 |
| NCT04024462 | Active, not recruiting | Phase 3 | A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer | February 5, 2020 | November 11, 2025 |
| NCT02366130 | Completed | Phase 2 | Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | February 11, 2015 | December 16, 2020 |
| NCT00044291 | Completed | Phase 3 | Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | June 2002 | January 2006 |
| NCT03493854 | Completed | Phase 3 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | June 14, 2018 | June 2, 2023 |
| NCT06083766 | Recruiting | Metabolic and Physiologic Responses to Hormone Therapy in Transgender and Gender Diverse People | January 4, 2024 | July 2026 | |
| NCT04134260 | Recruiting | Phase 3 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer | March 5, 2020 | November 1, 2026 |
| NCT04915508 | Recruiting | Phase 2 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy | June 23, 2021 | August 1, 2027 |
| NCT05041842 | Recruiting | Phase 2 | Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | December 17, 2021 | March 30, 2026 |
| NCT05448547 | Recruiting | Phase 3 | Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer | November 4, 2022 | December 31, 2036 |
| NCT05717166 | Recruiting | Phase 3 | A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. | October 6, 2023 | April 2029 |
| NCT00097344 | Terminated | Phase 3 | The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | December 2004 | August 2006 |
| NCT02855632 | Unknown status | N/A | The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis | August 2016 | December 2019 |
| NCT00227773 | Withdrawn | Phase 2 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | ||
| NCT00003517 | Withdrawn | Phase 2 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | ||
| NCT00080613 | Withdrawn | Phase 2 | Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer |